drugset / Trial / NCT01814020

An Open,Single-centre Pilot Study of Efficacy and Safety of Topical MOB015B in the Treatment of Distal Subungual Onychomycosis (DSO)

NCT01814020

Phase 2 Completed Moberg Pharma AB

Summary

Assess efficacy and safety of topical MOB015B, applied daily during 48 weeks, in adults with fungal nail infection.

Timeline

Start
2012-12
Primary completion
2014-07
Completion
2014-07

Drugs

EvaluationDrugModalityDoseRoute
Subject MOB015B Unknown Topical

Indications